<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03326791</url>
  </required_header>
  <id_info>
    <org_study_id>2014/2217</org_study_id>
    <nct_id>NCT03326791</nct_id>
  </id_info>
  <brief_title>Aspirin in Colorectal Cancer Liver Metastases</brief_title>
  <acronym>ASAC</acronym>
  <official_title>Acetylsalicylic Acid as Secondary Prevention in Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KLINBEFORSK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ASAC trial is a Scandinavian, multi-center, double-blinded, randomized,
      placebo-controlled study to determine whether adjuvant treatment with low-dose
      acetylsalicylic acid (ASA) can improve disease free survival in patients treated with
      resection for colorectal cancer liver metastases (CRCLM).

      Several studies have shown beneficial effect of ASA on primary prevention of CRC and the
      investigators group and others have shown a potential association of ASA also taken after the
      diagnosis on CRC survival in registry-based studies (secondary prevention). Up to 800
      patients operated for CRCLM will be randomized to Arm#1 ASA 160 mg once daily or Arm#2
      Placebo for a period of 3 years or till disease recurrence. The patients will be treated and
      followed up according to standard of care and the National Guidelines.

      The ASAC trial will be the first clinical interventional trial to assess the beneficial role
      of ASA in recurrence of CRC liver metastases and survival. ASA is an inexpensive, well
      tolerated, and easily accessible drug that will be highly potential as adjuvant drug in
      secondary prevention of CRC liver metastases if the study shows a beneficial effect. This
      trial will also investigate the effect of ASA as adjuvant treatment on Health-related Quality
      of Life and the cost-effectiveness.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-centre, double-blinded, randomized, placebo-controlled clinical intervention trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Eligible patients will be allocated in a 1:1 ratio using a computer randomization procedure stratified by centre. The randomization will be blocked within each stratum.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS) after three years treatment</measure>
    <time_frame>3 years</time_frame>
    <description>DFS three years after initiation of treatment with ASA or Placebo after resection of liver metastases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence (TTR) of disease after randomization</measure>
    <time_frame>3 years</time_frame>
    <description>Time to recurrence of liver metastases three years after start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) three years after treatment start</measure>
    <time_frame>3 years</time_frame>
    <description>OS at three years after initiation of treatment with ASA or Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life with 36-item Short Form Health Survey (SF-36)</measure>
    <time_frame>3 years</time_frame>
    <description>SF-36 has been proven useful in monitoring population health, estimating the burdens of different diseases, monitoring outcome in clinical practice, and evaluating medical treatment effects. Health-related Quality of Life (HR-QoL) will be assessed with SF-36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life with EuroQoL 5 Dimensions (EQ-5D)</measure>
    <time_frame>3 years</time_frame>
    <description>The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale. This will be used as a quantitative measure of health outcome that reflects the patient's own judgement. The scores on these five dimensions will be presented as a health profile. Health-related Quality of Life (HR-QoL) will be assessed with EuroQoL 5 Dimensions (EQ-5D).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASA in CRC and Cost-Effectiveness Analyses I</measure>
    <time_frame>3 years</time_frame>
    <description>Changes in HR-QoL will be used in calculation of the quality-adjusted life-year (QALY), a key outcome used in economic evaluations to compare treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASA in CRC and Cost-Effectiveness Analyses II</measure>
    <time_frame>3 years</time_frame>
    <description>Cost-effectiveness measured from a health care perspective by assessing the use of Health care provider in primary and specialized medicine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASA in CRC and Cost-Effectiveness Analyses III</measure>
    <time_frame>3 years</time_frame>
    <description>Cost-effectiveness measured from a societal perspective by assessing records in Statistics Norway (SSB).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Colorectal Cancer Liver Metastases</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acetylsalicylic acid 160 mg once daily until recurrent disease or a total period of 3 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral Tablet once daily until recurrent disease or a total period of 3 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>Trombyl 160 mg once daily</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Trombyl</other_name>
    <other_name>Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo one tablet daily</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First time CRCLM (synchronous or metachronous).

          -  Recurrence of CRCLM (not previously included in this trial).

          -  Macroscopic (surgical) free resection margins (R0 or R1 resection).

          -  Must be ambulatory with a performance status Eastern Cooperative Oncology Group (ECOG)
             0-2.

          -  Must be at least 18 years of age.

          -  Signed informed consent and expected cooperation of the patients for the treatment and
             follow up must be obtained and documented according to International Conference on
             Harmonization - Good Clinical Practice (ICH GCP), and national/local regulations.

        Exclusion Criteria:

          -  Concomitant use of ASA or other anticoagulants or platelet inhibitors such as warfarin
             or clopidogrel.

          -  Ongoing regular use of corticosteroids or NSAIDs.

          -  Inherited or acquired coagulopathy (haemophilia).

          -  Blood platelets (thrombocytes) &lt; 100 x 10^9/L.

          -  Severe heart failure (classified as New York Heart Association (NYHA) class &gt;III)

          -  Severe kidney failure.

          -  CRCLM previously treated with radiofrequency or microwave ablation technique

          -  Pregnancy or breastfeeding. For women in childbearing age there will be pregnancy test
             at monthly intervals (urine human chorionic gonadotropin (HCG) pregnancy tests (for
             home testing) will be given to the patients for monthly tests and the patient will
             self-report the results at each control). Furthermore, highly effective contraceptives
             will be required.

          -  Childbearing potential without proper contraceptive measures such as oral
             contraceptives, other hormonal contraceptives (vaginal products, skin patches, or
             implanted or injectable products), or mechanical products such as an intrauterine
             device to avoid pregnancy for the entire study period.

          -  Liver cirrhosis with a Child-Pugh score &gt;B7.

          -  Alcoholism.

          -  Contraindication listed on the Summary of Product Characteristics (SmPC) of Trombyl:
             Hypersensitivity/allergies to ASA, Thrombocytopenia, Previous severe gastrointestinal
             haemorrhage/peptic ulcer due to ASA/NSAID, Active peptic ulcer, Haemophilia, Liver
             cirrhosis, Severe congestive heart failure.

          -  Need to use concomitant medications contraindicated according to SmPC of Trombyl.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjørn A Bjørnbeth, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kjetil Taskèn, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheraz Yaqub, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anja Kokvoll, Nurse</last_name>
    <phone>+4747908528</phone>
    <email>anjkok@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victoria Bringsjord, Nurse</last_name>
    <phone>+4747908528</phone>
    <email>vicbri@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank V Mortensen, MD PhD</last_name>
      <phone>+4578459006</phone>
      <email>franmort@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter N Larsen, MD PhD</last_name>
      <phone>+4527104290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus Fristrup, MD PhD</last_name>
      <email>Claus.Wilki.Fristrup@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arild Horn, MD PhD</last_name>
      <phone>+4792034290</phone>
      <email>arild.horn@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheraz Yaqub, MD PhD</last_name>
      <phone>+4790953996</phone>
      <email>shya@ous-hf.no</email>
    </contact>
    <contact_backup>
      <last_name>Bjørn A Bjørnbeth, MD PhD</last_name>
      <phone>+4747287853</phone>
      <email>bbjoer@ous-hf.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jon Arne Søreide, MD PhD</last_name>
      <phone>+4790531770</phone>
      <email>jonarne.soreide@mac.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North-Norway</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Erlend Mortensen, MD PhD</last_name>
      <email>Kim.Erlend.Mortensen@unn.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jon Erik Grønbech, MD PhD</last_name>
      <phone>+4790546058</phone>
      <email>jon.e.gronbech@ntnu.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgranska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magnus Rizell, MD PhD</last_name>
      <phone>+46705259301</phone>
      <email>magnus.rizell@surgery.gu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Sandström, MD PhD</last_name>
      <email>per.sandstrom@liu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skåne University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gert Lindell, MD PhD</last_name>
      <phone>+4646176288</phone>
      <email>gert.lindell@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Sparelid, MD PhD</last_name>
      <email>ernesto.sparrelid@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Umeå</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oskar Hemmingsson, MD PhD</last_name>
      <email>oskar.hemmingsson@umu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bengt Isaksson, MD PhD</last_name>
      <phone>+46736994477</phone>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.asac.no/</url>
    <description>Website</description>
  </link>
  <link>
    <url>https://kliniskestudier.helsenorge.no/tykktarmskreft-kan-acetylsalisylsyre-hindre-tilbakefall-av-spredning</url>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Sheraz Yaqub</investigator_full_name>
    <investigator_title>MD PhD, Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>Acetylsalicylic acid</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Trombyl</keyword>
  <keyword>Secondary prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

